Preemptive interferon-α treatment could protect against relapse and improve long-term survival of ALL patients after allo-HSCT.

Scientific Reports
Sining LiuXiaodong Mo

Abstract

Relapse was the major cause of treatment failure in patients with acute lymphoblastic leukemia (ALL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We aimed to identify the efficacy and safety of preemptive interferon-α (IFN-α) treatment in ALL patients who had minimal residual disease (MRD) after allo-HSCT. Multiparameter flow cytometry and polymerase chain reaction assays were applied for MRD monitoring. Recombinant human IFN-α-2b injections were administered subcutaneously twice weekly in every 4 weeks cycle. Twenty-four (35.3%), 5 (7.4%), 6 (8.8%), and 13 (19.1%) patients achieved MRD negativity at 1, 2, 3, and > 3 months, respectively, after treatment. Seven patients showed grade ≥ 3 toxicities after IFN-α treatment. The 4-year cumulative incidence of total acute graft-versus-host disease (aGVHD), severe aGVHD, total chronic GVHD (cGVHD), and severe cGVHD after treatment was 14.7%, 2.9%, 40.0%, and 7.5%, respectively. The 4-year cumulative incidences of relapse and non-relapse mortality after treatment was 31.9% and 6.0%, respectively. The 4-year probabilities of disease-free survival and overall survival after IFN-α treatment were 62.1% and 71.1%, respectively. Thus, preemptive IFN-α treatment could...Continue Reading

Associated Clinical Trials

References

May 10, 1979·The New England Journal of Medicine·P L WeidenR Storb
Dec 13, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Alexandra H FilipovichMary E D Flowers
Jul 9, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Huang Xiao-JunTang Fei-Fei
Jan 29, 2011·Leukemia·S AnguilleE L J M Smits
Apr 27, 2012·British Journal of Haematology·Fiona L DignanUNKNOWN British Society for Blood and Marrow Transplantation
Apr 27, 2012·British Journal of Haematology·Fiona L DignanUNKNOWN British Society for Blood and Marrow Transplantation
Jun 28, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Xiao-Dong MoXiao-Jun Huang
Dec 29, 2016·Experimental Hematology·Guillermo OrtiDavid Valcarcel
May 2, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Xiao-Dong MoXiao-Jun Huang
Feb 1, 2018·The New England Journal of Medicine·Jae H ParkMichel Sadelain
Sep 6, 2018·Journal of the National Comprehensive Cancer Network : JNCCN·Ndiya OgbaSteven T Rosen
Feb 28, 2019·Blood Advances·Moshe YeshurunVeronika Bachanova

❮ Previous
Next ❯

Citations

Jul 25, 2021·Cancers·Emanuele CenciniMonica Bocchia

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
PCR

Clinical Trials Mentioned

NCT02185261

Software Mentioned

SPSS
R

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.